COVID-19 may accelerate the development of type 1 diabetes in kids

Embargoed until: Publicly released: 2024-07-16 01:00

International

CC-0. https://www.pexels.com/photo/structure-of-a-coronavirus-3993212/

Catching COVID-19 may speed up the development of type 1 diabetes in children, according to German researchers. They studied 591 kids with presymptomatic type 1 diabetes between 2015 and 2023. They followed 358 kids up until March 2020, or before the pandemic, and 396 after March 2020, or during the pandemic. During the pre-pandemic period, 57 kids progressed to type 1 diabetes, while during the pandemic period, 113 kids progressed, so the rate roughly doubled after COVID-19 arrived. Of the 396 participants followed up since the pandemic, 353 had COVID-19 infection information. Of these, 236 had a COVID-19 infection, the scientists say. Crunching the numbers, they found having had COVID-19 roughly doubled the incidence of progression from asymptomatic to full-blown type 1 diabetes, so the accelerated progression only happened in kids with COVID-19. Further studies are required to determine whether COVID-19 also accelerates progression to type 1 diabetes in adults, the scientists say.

Media release

From: JAMA

About The Study: Follow-up of youth with pre-symptomatic type 1 diabetes demonstrated that the COVID-19 pandemic was associated with an accelerated progression to clinical disease and that this acceleration was confined to those with COVID-19. Further studies are required to determine whether COVID-19 also accelerates progression to type 1 diabetes in adults and whether vaccination and monitoring for COVID-19 symptoms should be considered for individuals with pre-symptomatic type 1 diabetes.

Attachments

Note: Not all attachments are visible to the general public. Research URLs will go live after the embargo ends.

Research JAMA, Web page The URL will go live after the embargo ends

Journal/
conference: JAMA

Research:Paper

Organisation/s: German Center for Environmental Health, Germany

Funder: This work was supported by grants KKZ01KX1818 from the Federal Ministry of Education and Research (BMBF), G-2017PG-T1D023 from the Leona M. and Harry B. Helmsley Charitable Trust, NNF22SA0081044 from the Novo Nordisk Foundation (the 2022 EASD-Novo Nordisk Foundation Diabetes Prize for Excellence); and a grant from the Deutscher Diabetiker Bund. The Fr1da study was also supported by grants 1-SRA-2014–310-M-R, 3-SRA-2015–72-M-R, 3-SRA-2019–718-Q-R from JDRF International, HMGU 2014.01 and HMGU 2016.01 from LifeScience Stiftung, G-1911–3274 from the Leona M. and Harry B. Helmsley Charitable Trust, and from the German Center for Diabetes Research.

Media Contact/s

Contact details are only visible to registered journalists.